New Stock News | Weijian Pharmaceutical Submits Application to Hong Kong Stock Exchange

According to the disclosure of the Hong Kong Stock Exchange on November 7th, Vechain International Holdings Group Limited (Vechain Pharmaceuticals) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. According to the prospectus, Vechain Pharmaceuticals is a leading comprehensive pharmaceutical company in China that focuses on the treatment of kidney and blood diseases, with comprehensive strength in drug development, production, and commercialization. Vechain Pharmaceuticals is committed to addressing the significant clinical needs in the treatment of kidney and blood diseases and other major diseases by providing innovative and valuable treatment solutions. The prospectus mentions that Vechain Pharmaceuticals has built a diverse and differentiated product portfolio that extensively covers the fields of kidney and blood diseases and extends to other major disease areas such as respiratory and skin diseases. According to data from Zhishi Consulting, as of the last feasible date, Vechain Pharmaceuticals' product portfolio includes six kidney drugs, making it the pharmaceutical company in China with the largest number of commercialized original drugs for treating kidney diseases.